Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice.
First-in-class therapy showed an 83% (52/63) overall remission ratein this patient population with limited treatment options and historically poor outcomes [1],[2].
With the approval of Kymriah, we are once again delivering on our commitment to change the course of cancer care."
Novel approach to cancer treatment is the result of pioneering CAR-T cell therapy collaboration with University of Pennsylvania
Reproducible, flexible and validated manufacturing process builds on years of global clinical trial experience at our facility in New Jersey, US
Novartis also announces innovative collaboration with the US Centers for Medicare and Medicaid Services
Basel, August 30, 2017-Novartis announced today that the US Food and Drug Administration (FDA) has approved Kymriah(TM)(tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. Kymriah is a novel immunocellular therapy and a one-time treatment that uses a patient's own T cells to fight cancer. Kymriah is the first therapy based on gene transfer approved by the FDA.
"At Novartis, we have a long history of being at the forefront of transformative cancer treatment," said Joseph Jimenez, CEO of Novartis. "Five years ago, we began collaborating with the University of Pennsylvania and invested in further developing and bringing what we believed would be a paradigm-changing immunocellular therapy to cancer patients in dire need. With the approval of Kymriah, we are once again delivering on our commitment to change the course of cancer care."
"We are so proud to be part of this historic moment in cancer treatment and are deeply grateful to our researchers, collaborators, and the patients and families who participated in the Kymriah clinical program," said Bruno Strigini, CEO of Novartis Oncology. "As a breakthrough immunocellular therapy for children and young adults who desperately need new options, Kymriah truly embodies our mission to discover new ways to improve patient outcomes and the way cancer is treated."
The FDA has approved a Risk Evaluation and Mitigation Strategy (REMS) for Kymriah. The REMS program serves to inform and educate healthcare professionals about the risks that may be associated with Kymriah treatment. To support safe patient access, Novartis is establishing a network of certified treatment centers throughout the country which will be fully trained on the use of Kymriah and appropriate patient care.
There has been an urgent need for novel treatment options that improve outcomes for patients with relapsed or refractory (r/r) B-cell precursor ALL, whose prognosis is poor. Patients often undergo multiple treatments including chemotherapy, radiation, targeted therapy or stem cell transplant, yet less than 10% of patients survive five years [2], [3].
Kymriah is an innovative immunocellular therapy that is a one-time treatment. Kymriah uses the 4-1BB costimulatory domain in its chimeric antigen receptor to enhance cellular expansion and persistence. In 2012, Novartis and the University of Pennsylvania (Penn) entered into a global collaboration to further research, develop and commercialize CAR-T cell therapies, including Kymriah, for the investigational treatment of cancers.
"This therapy is a significant step forward in individual...
Read More
Related News
Comparison of Improved New Drugs Paths between China and the United States and Analysis of R&D Status in China
Kevin April 28, 2025
Cryoport to Support ProMab’s CAR-T Services
contractpharma January 18, 2017
Adents Ramps Up U.S. Ops
contractpharma January 18, 2017
You may like
Vacuum suction cup hanger steel plate high temperature aluminum plate suction cup titanium plate and other metal plate suction cup under 30 tons
3 tons of aluminum plate vacuum suction cup hanger can set high quality plate suction cup hanger
Supply nitrile rubber suction cup HFG-200 vacuum suction cup spreader high temperature suction cup
Orforglipron
Tempered glass suction cup hanger, glass deep processing handling lifting suction cup, glass 90 degree flip suction crane
(All Rights Reserved)